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818 | Anal. Methods, 2015, 7, 818–824tiﬁcation and quantiﬁcation of
volatile biomarkers released by cystic ﬁbrosis
pathogens
F. J. Gilchrist,*ab P. Sˇpaneˇl,c D. Smithb and W. Lenneyab
There is interest in the development of exhaled breath tests for the detection of lower airway infection in
children with cystic ﬁbrosis. The ﬁrst stage of this process is the identiﬁcation of volatile organic
compounds (VOCs) released into the gas phase by CF pathogens that can be used as breath test
biomarkers. Selected ion ﬂow tube mass spectrometry (SIFT-MS) is ideally suited to these in vitro studies
as it allows simultaneous quantiﬁcation of multiple VOCs in real time. We review a decade of in vitro
experiments using SIFT-MS to analyse the VOCs released by respiratory pathogens. This includes
identiﬁcation and quantiﬁcation of VOCs and the investigation of the in vitro factors that aﬀect their
production. We also report on how our culture methodology has been reﬁned over the years to better
account for variations in bacterial mass. Finally, we discuss how these in vitro ﬁndings have been
translated into clinical trials and assess possible future applications.Introduction
CF is the commonest inherited life-limiting condition in the
Caucasian population aﬀecting over 10 000 patients in the
United Kingdom.1 It is characterised by recurrent pulmonary
infections leading to chronic inammation, respiratory failure
and death. The early and accurate detection of respiratory
infections is a vital component of good CF care and is associated
with reduced morbidity and mortality.2 This is diﬃcult in
children who are oen unable to expectorate sputum for
microbiological culture. There is an urgent need for a non-
invasive, child-friendly method to detect pulmonary infections
in such children. One exciting possibility is the use of exhaled
breath tests.3 The concept of an exhaled breath test to detect a
lower airway infection in children with CF was considered by
our team aer a number of patients were noted to have halitosis
around the time they acquired a respiratory infection with one
of the most important CF pathogens, Pseudomonas aeruginosa
(PA). We believed that if a characteristic smell was present, then
it should be possible to quantify this. The non-invasive and
child-friendly nature of exhaled breath tests makes this a very
appealing way of diagnosing lower airway infection in children
with CF who cannot expectorate sputum. The potential for
signicant clinical value has driven our programme of research.yal Stoke University Hospital, ST4 6QG,
t@uhns.nhs.uk; Fax: +44 0843 6365389;
icine, Keele University, ST4 7QB, UK
try, Academy of Sciences of the CzechThe rst stage in the development of an exhaled breath test
for the detection of a respiratory pathogen is the in vitro
detection of volatile organic compounds (VOCs) that can
potentially be used as biomarkers.4,5 Identied VOCs must then
be quantied and factors aﬀecting their production estab-
lished.6–8 The second stage involves the analysis of exhaled
breath samples taken from patients known to have pulmonary
infection with the relevant pathogen.9,10 This investigates if the
VOCs identied in vitro can also be identied in vivo and
attempts to assess the eﬀect of host factors such as co-infection,
dietary intake and diurnal variation.11,12 If conrmed, further
studies may be undertaken to investigate if the VOCs are
detectable in exhaled breath early enough aer new infection to
allow them to be used as a screening test. This review will focus
on the rst stage of this process, specically the methodologies
used for the in vitro identication and quantication of the
biomarkers of CF pathogens. The second stage is clearly of
equal importance but is beyond the scope of this review. Our
team has over a decades experience in the analysis of VOCs
released into the gas phase by cultures of CF pathogens.13 Our
work initially focussed on PA as this is the most important CF
pathogen but more recently we have investigated Staphylococcus
aureus (SA), Streptococcus pneumoniae (SP), Haemophilus inu-
enzae and Aspergillus fumigatus (AF). See Fig. 1.Methods of VOC analysis
There are a number of diﬀerent analytical techniques that have
been used to identify the VOCs released into the gas phase by in
vitro cultures. These include but are not limited to selected ion
ow tube mass spectrometry (SIFT-MS),6 gas chromatographyThis journal is © The Royal Society of Chemistry 2015
Fig. 1 The timeline of the research programme directed towards the study of gaseous HCN as a biomarker of PA infection in CF. The upper part
of the scheme traces the in vivo studies with human subjects and the lower part traces the related parallel in vitro studies. Reproduced with
permission from Smith et al.13
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View Article Onlinemass spectrometry (GCMS),14 proton transfer reaction mass
spectrometry (PTR-MS),15 ion mobility spectrometry (IMS).16 A
detailed review of each of these techniques is beyond the scope
of this review but each has relative pro and cons.17 The tech-
nique most frequently used by our team is SIFT-MS and this will
therefore be discussed in more detail.Selected ion ow tube mass spectrometry
SIFT-MS combines fast ow tube reactors and quantitative mass
spectrometry to allow accurate real-time quantication of VOCs
down to a concentration of close to one part per billion by
volume (ppbv).18,19 See Fig. 2. The ability to give absolute, real
time quantication of a number of compounds simultaneouslyFig. 2 The SIFT-MS Instrument. Used with permission from Sˇpaneˇl et al
This journal is © The Royal Society of Chemistry 2015makes SIFT-MS ideally suited to non-invasive and direct anal-
ysis of culture headspace. A mixture of precursor (reagent) ions
is generated in a discharge ion source. The appropriate ion
species (H3O
+, NO+ or O2
+) is mass selected by a quadrupole
mass lter, according to the compounds to be quantied, and
then injected as selected ionic species into fast-owing helium
carrier gas in a ow tube. The gas to be analysed (in this case the
culture headspace) is sampled directly into the carrier gas/
precursor ion swarm at a known rate via a calibrated capillary.
The reagent ions react with the trace gases in the sample
producing ions that are characteristic of the trace gas mole-
cules. These characteristic product ions, and the precursor ions
and their hydrates are detected and counted by a downstream
quadrupole mass spectrometer/ion detection system. An on-line.21
Anal. Methods, 2015, 7, 818–824 | 819
Fig. 3 SIFT-MS spectra of Pseudomonas aeruginosa culture headspace using H3O
+ precursor ions. Expected compounds in culture headspace
included ammonia, methanethiol, methanol and acetone. Compounds have multiple peaks due to the addition of water molecules. The peaks at
m/z 28 and 46 were unexpected and identiﬁed as HCN. Used with permission from Sˇpaneˇl et al.31
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View Article Onlinecomputer calculates the partial pressures of the trace gases in
the air sample from the precursor ion and characteristic
product ion count rates and the sample gas ow rate as estab-
lished by the calibrated capillary.20
SIFT-MS instruments can be operated in ether the full scan
(FS) or the multiple ion monitoring (MIM) mode. Using the full-
scan (FS) mode a complete mass spectrum is obtained by
sweeping the detection quadrupole over a chosen mass–charge
ratio (m/z) range. This is done for a selected time whilst a sample
of air or breath is introduced into the carrier gas at a steady ow
rate. The count rates of the ions are then calculated from the
numbers of counts and the total sampling time for each ion. The
mass spectra are interpreted by relating the product ion peaks to
the trace gases present in the sample from a detailed knowledge
of the ion chemistry and the in-built database. An example is
shown in Fig. 3. This mode is used in the initial experiments to
identify the VOCs released by particular organism. In the MIM
mode, only the count rates of the precursor ions and those of
selected product ions are monitored. This is achieved by rapidly
switching the downstream mass spectrometer between the
masses of all the primary ions and the selected product ions and
dwelling on each of these masses for a predetermined short time
interval, which eﬀectively increases the analysis time and hence
the precision of measurement. This real-time monitoring is
possible because of the fast time response of SIFT-MS, which is
about 20 milliseconds and is largely determined by the fast
ow rates of the carrier gas along the ow tube and the sample
gas along the inlet tube. There is no fundamental limit to the
number of diﬀerent ion masses that can be recorded simulta-
neously using this technique, but fewer ions result in greater
analytical precision within a given analytical time frame.21 The
MIMmode is used once the VOCs of interest have been identied
and the aim of the experiment changes from identication to
quantication.
Methodology of culture headspace
analysis
The aim analysing culture headspace using SIFT-MS is to ach-
ieve high quality sampling with little or no disturbance of
the culture.7 To achieve this, the cultures are prepared, sealed820 | Anal. Methods, 2015, 7, 818–824inside individual low-density polyethylene (LDPE) bags and
then incubated. At the time of analysis, the bag is punctured
with a hypodermic needle connected directly to the sample
input port of the SIFT-MS instrument. The needle is carefully
placed so that it is in the headspace but does not come into
direct contact with the culture (see Fig. 2). The gas/vapour
developed above the cultures is introduced at a set ow rate (via
a heated calibrated capillary) into the carrier gas of the SIFT-MS
instrument. The sample can be analysed using either the FS or
MIM mode of SIFT-MS. When the MIM is used, the sample is
analysed for 100 seconds and the mean concentrations of the
relevant compounds are recorded over this time. Following
analysis, the hypodermic needle is removed whilst keeping the
bag sealed, the lid replaced and the puncture hole le by the
needle covered with tape. This methodology allows the culture
headspace of a single culture to be analysed at multiple dura-
tions of incubation with minimal disruption to the culture
itself. Whenever cultures are analysed in this way it is also
necessary to analyse control cultures. These are samples of
sterile culture medium (agar or liquid) that are sealed in LDPE
bags and incubated using the same methodology as the
cultures. Comparison of the VOCs released into the gas phase
by the cultures and control cultures conrms which are released
by the bacteria and which are released by the culture medium
or LDPE bags.Culture preparation
Agar plate cultures
Our initial studies used simple agar plate cultures.4,6,7 Clinical
isolates were plated out onto the appropriate agar plate, covered
with a lid, sealed in an individual LDPE bag (127 mm 203 mm)
and incubated. When the headspace was sampled the lid was
lied to allow the needle attached to the sample input port of the
SIFT-MS to be sited in the headspace whilst keeping the bag
sealed. Aer analysis, the needle was removed, the lid replaced
and the puncture hole sealed with tape. The main disadvantage
of using agar plate cultures is that it is not possible to account for
the eﬀect of bacterial mass which will potentially aﬀect the
quantity of VOCs produced by a culture.This journal is © The Royal Society of Chemistry 2015
Fig. 4 Headspace analysis of a bioﬁlm culture of Pseudomonas aer-
uginosa using SIFT-MS. Used with permission of Gilchrist et al.7
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View Article OnlineLiquid cultures
In an attempt to standardise the bacterial mass, liquid cultures
were used in our later studies.7,22–24 The bacteria sample was
initially cultured overnight on agar, the colonies that formed
then used to produce saline suspensions. The turbidity of the
suspensions was adjusted to approximately 0.5 optical density
units (assessed using a spectrophotometer at 600 nm), which
approximates to 108 colony forming units (CFUs) per mL. 150
mL glass bottles containing 10 mL of the appropriate liquid
media were then inoculated with 0.5 mL of the saline suspen-
sion. The bottles were immediately sealed with lids containing a
rubber septum and incubated without agitation. The quantity of
cells in each inoculum was additionally assessed by plating 105
fold dilutions of the saline suspensions onto agar plates, which
were incubated for 24 h aer which the colonies were counted.
The headspace of the liquid cultures was sampled by
piercing the rubber septum with a hypodermic needle con-
nected directly to the sample inlet port of the SIFT-MS instru-
ment. The headspace volume over the 10 mL liquid culture was
typically 140 mL. A sample ow rate of 30 mL min1 was used
and the pressure in the bottle was maintained at atmospheric
pressure by balancing the loss of headspace gas/vapour by a
exible bag containing dry sterile cylinder air. During the
sampling period of 100 seconds, a temporary dilution of the
headspace occurred resulting in a small reduction in the VOC
concentrations. Headspace/liquid phase equilibrium in the
VOC concentrations was rapidly re-established.22,23Planktonic and biolm cultures
A number of CF pathogens, including Pseudomonas aeruginosa
(PA) and Burkholderia cepacia complex (BCC), are able to form
biolms.8 During early pulmonary infection, these organisms
attach to the respiratory epithelium and multiply whilst in a
planktonic (free-oating) form. Once a certain bacterial density
is reached, growth slows and biolm production is signalled.
This signalling occurs by quorum sensing in which extra-
cellular molecules are used to regulate phenotype in response to
population density.25 Biolms are communities of non-motile
organisms embedded in an exopolysaccharide matrix attached
to a solid surface.26When growing in this form, these organisms
are more diﬃcult to remove by mucociliary clearance and
have increased antibiotic resistance.27 A mucoid phenotype is a
marker of biolm formation.28
As a number of quorum sensing molecules are known to be
volatile, it was important to be able to produce in vitro biolm
cultures to assess their eﬀect on the pattern of headspace
VOCs.7,24 Initially a liquid culture was produced, as detailed
above; 10 mL of this liquid culture was pipetted into a sterile
Petri dish containing 4 mm diameter sterile glass beads (suﬃ-
cient to evenly cover the bottom of the Petri dish). A lid was then
placed on the Petri dishes and the dish sealed in an individual
LDPE bag and incubated. The liquid media was changed daily
by pipetting oﬀ approximately 10 mL of spent media and
replacing with 10 mL of fresh media.7,24 Planktonic cultures
were created by pipetting the liquid culture in to a Petri
dish that did not contain glass beads; all other aspects of theThis journal is © The Royal Society of Chemistry 2015preparation and analysis was identical to the biolm cultures.
This technique was adapted from previously published papers.29
The biolm forms around the glass beads during the next 48–
72 hours (see Fig. 4).
Biolm formation was assessed visually on a daily basis and
then quantied using spectrophotometry aer 96 hours (aer
headspace analysis had been completed). To do this, individual
glass beads were removed from the culture and washed in crystal
violet that penetrates the bacteria cell wall and membrane. Each
bead was then submerged in a dened volume of industrial
methylated spirits (IMS) to solubilise the biolm. The IMS (con-
taining the solubilised biolm) was analysed using the spectro-
photometer set at 600 nm. As the number of bacteria in the
biolm increases, the aqueous concentration of crystal violet
increases which causes increased absorbance. This method of
assessing biolm formation is well established,29 a possible
criticism of this method is that it is actually assessing bead
adherence and not biolm formation. True biolm formation
can be assessed by the detection of non-volatile quorum sensing
signalling molecules, but we do not have this facility in our
laboratory.30VOCs released by cultures of PA
Detection of hydrogen cyanide
The VOCs released by in vitro cultures of PA were the rst that
our team analysed.4 Using the H3O
+ precursor ions, the SIFT-MS
FS spectrum reveals the presence of several VOCs. Unusually, it
consistently showed product ions with mass-to-charge-ratio
(m/z) of 28 and 46 (see Fig. 3). These ions were not present at
signicant levels in the headspace of control cultures (see
Fig. 5). The product ion with anm/z value of 28 was identied as
protonated HCN (H2CN
+). C2H4
+, N2
+ and CO+ were excluded as
possibilities as they cannot be formed in the reaction of H3O
+
with either C2H4, N2 and CO (all with molecular mass of 28). It
follows from the known ion chemistry of HCN, as investigated
thoroughly in our extensive study, that the product ion atm/z 46
is HCNH+$H2O, the monohydrate of protonated HCN.31 This
thorough study of the ion chemistry of HCN allowed the
required SIFT-MS kinetics database to be constructed, thereby
allowing accurate quantication of gaseous HCN in moist airAnal. Methods, 2015, 7, 818–824 | 821
Fig. 5 Volatile compounds detected in the headspace of Pseudomonas aeruginosa, upper respiratory tract ﬂora and blank cultures. Mean
concentration of volatiles in parts per billion (ppb). ** indicate statistical signiﬁcance of the diﬀerence (p < 0.05). Used with permission Carroll
et al.4
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View Article Onlinesamples. SIFT-MS studies then conrmed the presence of HCN
in the headspace of PA cultures. Although it had been known for
a number of years that PA can produce cyanide ions (CN), this
SIFT-MS study was the rst study to detect and quantify HCN
released into the gas phase by PA cultures, revealing it as a
possible biomarker in exhaled breath of PA infection of the
airways.
In total, 22 PA cultures and 13 control cultures (6 sterile
plates and 7 cultures of mixed upper respiratory tract ora
[URTF]) were analysed aer 48 hours incubation.4 HCN
was detected in the headspace of 15/22 PA and 1/7 URTF
cultures. The mean concentration of the 15 positive PA cultures
(2170 ppbv) was signicantly higher than the concentration of
the single positive URTF culture (60 ppbv) (see Fig. 5). Using a
headspace HCN of > 100 ppbv for the identication of PA gave a
sensitivity of 68% and a specicity of 100%. The other VOCs
identied, were not specic to PA.
Subsequently, to conrm that PA was the only CF pathogen
to produce HCN we analysed the culture headspace of multiple
samples of Streptococcus pneumoniae, Staphylococcus aureus,
Moraxella catarrhalis, Haemophilus inuenzae and Aspergillus
fumigatus. For all these organisms, the headspace HCN
concentration remained very low (<10 ppb) at all incubation
time points. The headspace HCN concentration in the control
cultures (sterile agar plates) also remained <10 ppbv at all
durations of incubation.6The eﬀect of genotype, phenotype and biolm formation
As part of a previous study assessing cross infection between
CF patients, 96 PA isolates obtained were genotyped and
then stored on cryogenic beads (Pro-Lab Diagnostics. Micro-
bankTM Product code PL 172) at 70 degrees Celsius. Aer
gaining ethical approval, we analysed the HCN released into822 | Anal. Methods, 2015, 7, 818–824the headspace aer 24, 48, 72 and 96 hours of incubation.6
All 96 PA cultures had elevated HCN concentrations in the
culture headspace, but the quantity varied according to the PA
genotype.
Increased HCN concentrations were found in the head-
space of non-mucoid PA samples compared to mucoid
samples. This was in contrast to previous studies that identi-
ed elevated concentrations of the non-volatile ion cyanide
(CN) in mucoid PA cultures.32,33 One possible explanation for
this is that mucoid PA cultures do produce cyanide, but the
layer of alginate that covers mucoid cultures prevents this
from being released as HCN into the gas phase. It is again
important to emphasize that the SIFT-MS method of detecting
HCN in the culture headspace does not disrupt the culture in
contrast to the detection of cyanide using a cyanide ion-
selective electrode. Since any in vivo breath test for PA detec-
tion would be based on the analysis of VOCs, we focus on the
factors that aﬀect gaseous HCN (volatile) rather than cyanide
ions (non-volatile).
As HCN is a quorum sensing molecule, we expected the
formation of biolms to increase the production of HCN by PA
as seen with BCC.29 However, a subsequent study using a small
number of the same samples did not reveal any diﬀerence in
the headspace HCN concentration for biolm and planktonic
PA cultures.7 The likely explanation for this is related to our
explanation for the diﬀerence in the HCN production by non-
mucoid and mucoid PA cultures. This is, PA biolm cultures
do produce cyanide ions, but any gaseous HCN remains
trapped within the biolm and is therefore not released into
the gas phase. Our team and our collaborators have thor-
oughly investigated the other VOCs released into the gas
phase by cultures of PA, but HCN remains the most reliable
biomarker.34,35This journal is © The Royal Society of Chemistry 2015
Fig. 6 Bar plots of the concentrations of several compounds present in the headspace of sterile culture media (BHI) and cultures of Aspergillus
fumigatus (AF). Various durations of incubation: 24 h (open bars), 48 h (light grey bars) and 72 h (dark grey bars). Error bars indicate the standard
errors. Note the abbreviations DMS (dimethyl sulphide) and DMDS (dimethyl disulphide). Used with permission from Chippendale.23
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View Article OnlineVOCs released by other CF pathogens
Staphylococcus aureus (SA)
The headspace of liquid SA cultures was analysed using SIFT-
MS in FS mode at various period of incubation. Control cultures
(sterile culture medium) were analysed using the same meth-
odology. Six VOCs were present in higher concentration in
the SA headspace compared to the control cultures. These
were ammonia, methanol, acetaldehyde, ethanol, propanol and
pentanal.22Streptococcus pneumoniae (SP)
The VOCs released in the headspace above liquid SP cultures
were analysed using SIFT-MS in FS mode over various durations
of incubation. The medium used to culture SP was the same as
that used to culture SA. The same control cultures (sterile
culture medium) were therefore used. Eight VOCs were present
in higher concentration in the SP headspace compared to the
control cultures. These were methanol, acetaldehyde, ethanol,
acetone, propanol, butanal, butanone and pentanal. Unlike the
SA culture headspace, the concentrations of all of the identied
compounds continuously increased during the incubation
period. The ammonia concentration was lower in the SP head-
space compared to the control culture headspace. This is likely
related to the lower pH of the culture.22Aspergillus fumigatus (AF)
Using a similar methodology to the SA and SP experiments, the
headspace of liquid AF fungal cultures was compared to theThis journal is © The Royal Society of Chemistry 2015headspace of control cultures (sterile culture medium). High
concentrations of ammonia, methanethiol, dimethyl sulphide
and dimethyl disulphide were identied in the AF culture
headspace. The AF headspace had lower concentrations of
acetaldehyde, butanal and pentanal (see Fig. 6). Interestingly,
the VOCs emitted by co-cultures of AF with PA, SA and SP
revealed that the biomarker HCN (for PA) is not compromised
by the presence of AF, and the organosulphur compounds (for
AF) are not compromised by the presence of SA or SP.23Conclusions
The development of exhaled breath tests for the detection of
lower airway infections in children with CF could revolutionise
their care. The rst stage in this process is the in vitro identi-
cation of a VOC or a pattern of VOCs that is specic to that
organism. In the past decade our team has gained great expe-
rience in the microbiology and SIFT-MS techniques necessary to
identify and quantify potential volatile biomarkers. Our work
investigating HCN as marker of PA infection has demonstrated
that VOCs identied in the headspace of bacterial cultures can
be used as biomarkers in an exhaled breath test. We hope to
develop a similar programme of research in relation to other
respiratory pathogens including SA, SP and AF.References
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